Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement appears for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company.

This announcement is not for release, publication or distribution, in whole or in part, in or into any jurisdiction where to do so would constitute a violation of the applicable laws or regulations of such jurisdiction.

BioDlink International Company Limited
東曜藥業股份有限公司
(Incorporated in Hong Kong with limited liability)
(Stock Code: 1875)

ANNOUNCEMENT PURSUANT TO RULE 3.8 OF THE TAKEOVERS CODE

This announcement is made by BioDlink International Company Limited (the "**Company**") pursuant to Rule 3.8 of the Hong Kong Code on Takeovers and Mergers (the "**Takeovers Code**").

Reference is made to the joint announcement dated 14 January 2026 issued by the Offeror, Wuxi Biologics and the Company in relation to, among others, the Offers (the "**Announcement**") and the composite document jointly issued by the Company and the Offeror dated 12 February 2026 in connection with the Offers (the "**Composite Document**"). Unless the context otherwise requires, capitalised terms used herein shall have the same meanings as defined in the Announcement and the Composite Document.

UPDATE ON THE NUMBER OF RELEVANT SECURITIES OF THE COMPANY

The Company wishes to announce that, on 1 March 2026, 142,000 Share Options have vested.

Immediately after the aforementioned vesting of Share Options, the relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) issued by the Company comprise:

(a) 772,787,887 Shares in issue, out of which there are (i) 30,023,789 outstanding Vested RSA Shares in respect of which the full amount of the Grant Consideration had not been received by the Company; and 14,557,825 Unvested RSA Shares;

(b) 7,632,600 outstanding Share Options, comprising (i) 7,348,600 Vested Unexercised Options; and (ii) 142,000 Unvested Options.

Save as disclosed above, the Company has no other outstanding relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code) as at the date of this announcement.

DEALING DISCLOSURE

The respective associates (as defined in the Takeovers Code) of the Company and the Offeror, including persons holding 5% or more of the relevant securities (as defined in Note 4 to Rule 22 of the Takeovers Code), are hereby reminded to disclose their dealings in any relevant securities of the Company under Rule 22 of the Takeovers Code during the offer period.

In accordance with Rule 3.8 of the Takeovers Code, reproduced below is the full text of Note 11 to Rule 22 of the Takeovers Code:

"*Responsibilities of stockbrokers, banks and other intermediaries*

Stockbrokers, banks and others who deal in relevant securities on behalf of clients have a general duty to ensure, so far as they are able, that those clients are aware of the disclosure obligations attaching to associates of an offeror or the offeree company and other persons under Rule 22 and that those clients are willing to comply with them. Principal traders and dealers who deal directly with investors should, in appropriate cases, likewise draw attention to the relevant Rules. However, this does not apply when the total value of dealings (excluding stamp duty and commission) in any relevant security undertaken for a client during any 7 day period is less than $1 million.

This dispensation does not alter the obligation of principals, associates and other persons themselves to initiate disclosure of their own dealings, whatever total value is involved.

Intermediaries are expected to co-operate with the Executive in its dealings enquiries. Therefore, those who deal in relevant securities should appreciate that stockbrokers and other intermediaries will supply the Executive with relevant information as to those dealings, including identities of clients, as part of that co-operation."

WARNING

Shareholders, Option Holders and potential investors of the Company should note that Completion is subject to the Conditions being satisfied or, if capable of being waived, waived and therefore the Offers may or may not become unconditional and may or may not be completed.

Shareholders and Option Holders are reminded to read the Composite Document, including the recommendations of the Independent Board Committee and the advice of the Independent Financial Adviser in respect of the Offers, before deciding whether or not to accept the Offers applicable to them, respectively.

Shareholders, Option Holders and potential investors of the Company are advised to exercise caution when dealing in the Shares and other securities of the Company. If Shareholders, Option Holders and potential investors are in any doubt about their positions, they should consult their professional advisers.

By order of the Board
BioDlink International Company Limited
Mr. Fu, Shan
Executive Director

Hong Kong, 1 March 2026

As at the date of this announcement, the executive director of the Company is Mr. Fu, Shan; the non-executive director of the Company is Dr. Liu, Weidong; and the independent non-executive directors of the Company are Ms. Sun, Hui, Mr. Zhang, Qing and Dr. Gu, Xuelin.

The Directors jointly and severally accept full responsibility for the accuracy of the information contained in this announcement and confirm, having made all reasonable enquiries, that to the best of their knowledge, opinions expressed in this announcement have been arrived at after due and careful consideration and there are no other facts not contained in this announcement, the omission of which would make any statement in this announcement misleading.

This announcement is published in English and in Chinese. In case of any inconsistency between the English version and the Chinese version, the English version prevails.